Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline
- PMID: 28577058
- DOI: 10.1007/s00702-017-1740-9
Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline
Abstract
Type B monoamine oxidase (MAO-B) in glial cells has been considered to be associated with neuronal death in Parkinson's disease. MAO-B inhibitors, rasagiline and selegiline [(-)deprenyl], protect neurons in animal and cellular models of neurodegeneration. However, the role of MAO-B itself in the regulation of cell death processing remains elusive, whereas type A MAO (MAO-A) mediates the induction of anti-apoptotic Bcl-2 genes by rasagiline and selegiline. In this paper, the involvement of MAOs in the induction of neuroprotective genes by MAO inhibitors was investigated in human glioblastoma U118MG cells expressing mainly MAO-B. Selegiline significantly increased Mao-B, which was suppressed by Mao-A knockdown with short interfering (si)RNA, whereas rasagiline less markedly increased Mao-B, which was not affected by Mao-A knockdown. Mao-A mRNA was also markedly increased by rasagiline and selegiline, and Mao-B knockdown significantly enhanced the induction by selegiline, but not by rasagiline. Mao-B knockdown also significantly increased mRNA levels of Bcl-2, brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF). Selegiline synergistically enhanced the expression of these genes in Mao-B knockdown cells, but Mao-A knockdown suppressed the increase. Rasagiline increased BDNF and GDNF, which Mao-B and Mao-A knockdown inhibited. These results show that MAO-B might function as a repressor and MAO-A as a mediator in the constitutional expression of pro-survival genes, and that MAO-B and MAO-A might regulate different signal pathways for rasagiline and selegiline to induce neuroprotective genes. The novel role of glial MAOs in the regulation of gene expression is discussed.
Keywords: Bcl-2; MAO-B inhibitor rasagiline–selegiline; Neuroprotective gene induction; Neurotrophic factors BDNF–GDNF; Type B and A monoamine oxidase.
Similar articles
-
Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.J Neural Transm (Vienna). 2012 Apr;119(4):405-14. doi: 10.1007/s00702-011-0730-6. Epub 2011 Nov 8. J Neural Transm (Vienna). 2012. PMID: 22065207
-
Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.J Neural Transm (Vienna). 2013 Mar;120(3):435-44. doi: 10.1007/s00702-012-0899-3. Epub 2012 Sep 12. J Neural Transm (Vienna). 2013. PMID: 22968599
-
Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.Expert Rev Neurother. 2013 Jun;13(6):671-84. doi: 10.1586/ern.13.60. Expert Rev Neurother. 2013. PMID: 23739004 Review.
-
Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.J Neural Transm (Vienna). 2018 Nov;125(11):1635-1650. doi: 10.1007/s00702-017-1832-6. Epub 2017 Dec 26. J Neural Transm (Vienna). 2018. PMID: 29279995 Review.
-
Rasagiline and selegiline suppress calcium efflux from mitochondria by PK11195-induced opening of mitochondrial permeability transition pore: a novel anti-apoptotic function for neuroprotection.J Neural Transm (Vienna). 2015 Oct;122(10):1399-407. doi: 10.1007/s00702-015-1398-0. Epub 2015 Apr 12. J Neural Transm (Vienna). 2015. PMID: 25863936
Cited by
-
Alzheimer Disease and Selected Risk Factors Disrupt a Co-regulation of Monoamine Oxidase-A/B in the Hippocampus, but Not in the Cortex.Front Neurosci. 2018 Jun 26;12:419. doi: 10.3389/fnins.2018.00419. eCollection 2018. Front Neurosci. 2018. PMID: 29997470 Free PMC article.
-
Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings.Neural Regen Res. 2024 Jan;19(1):16-21. doi: 10.4103/1673-5374.375299. Neural Regen Res. 2024. PMID: 37488838 Free PMC article. Review.
-
Natural Products for Neurodegeneration: Regulating Neurotrophic Signals.Oxid Med Cell Longev. 2021 Jun 21;2021:8820406. doi: 10.1155/2021/8820406. eCollection 2021. Oxid Med Cell Longev. 2021. Retraction in: Oxid Med Cell Longev. 2024 Jan 9;2024:9854929. doi: 10.1155/2024/9854929. PMID: 34239696 Free PMC article. Retracted. Review.
-
Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.J Neural Transm (Vienna). 2020 Feb;127(2):131-147. doi: 10.1007/s00702-020-02150-w. Epub 2020 Jan 28. J Neural Transm (Vienna). 2020. PMID: 31993732 Review.
-
The roles and molecular mechanisms of long non-coding RNA WT1-AS in the maintenance and development of gastric cancer stem cells.Heliyon. 2023 Mar 21;9(4):e14655. doi: 10.1016/j.heliyon.2023.e14655. eCollection 2023 Apr. Heliyon. 2023. PMID: 37025896 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources